Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...

The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the firm's quarterly execution and forecast don't reflect its full potential.

To round out the rest of the recommendations, I asked jewelry designers, fellow collectors, and professional organizers about the jewelry boxes, catchalls, and stands they use and tried some of ...

That could help the healthcare stock stage a comeback. Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high sensitivity at a specificity ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million. The average estimate of six ...

After compiling and comparing all our in-house test data and analyzing thousands of customer reviews, we've crowned The DreamCloud Hybrid as this year's best mattress in a box. It offers great ...